FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch

Regular Mailing Address: 1600 Clifton Road, N.E.
Mail Stop F-57
Atlanta, Georgia 30329-4027

Physical Mailing Address: 4770 Buford Highway
Building 102, 1st floor, MS F-57
Chamblee, Georgia 30341

***DRAFT FOR PUBLIC COMMENT***
The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention
## VERSION HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2018</td>
<td>Draft for public comment toxicological profile released</td>
</tr>
<tr>
<td>August 2015</td>
<td>Draft for public comment toxicological profile released</td>
</tr>
<tr>
<td>May 2009</td>
<td>Draft for public comment toxicological profile released</td>
</tr>
</tbody>
</table>
CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Selene Chou, Ph.D. (Lead)
Dennis Jones, DVM, Ph.D.
Hana R. Pohl, M.D., Ph.D.
Patricia Ruiz, Ph.D.
Franco Scinicariello, M.D., M.P.H.
Melanie Buser, M.P.H.

Lisa Ingerman, Ph.D., DABT
Lynn Barber, M.S.
Heather Carlson-Lynch, M.S., DABT
Mario Citra, Ph.D.
Gary L. Diamond, Ph.D.
Julie Klotzbach, Ph.D.
Fernando T. Llados, Ph.D.
Daniel J. Plewak, B.S.

ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA
SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:
Includes ATSDR; National Center for Environmental Health (NCEH); National Institute of Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:
ATSDR, Division of Community Health Investigations; EPA; NCEH, Division of Laboratory Science.

PEER REVIEWERS

1. David A. Savitz, Ph.D., Professor of Epidemiology, Professor of Obstetrics and Gynecology, Brown University, Providence, Rhode Island

2. Deborah A. Cory-Slechta, Ph.D., Professor of Environmental Medicine, Pediatrics and Public Health Sciences, Acting Chair, Department of Environmental Medicine, PI, NIEHS Center of Excellence, Department of Environmental Medicine, University of Rochester Medical Center, Rochester, New York

3. Jamie DeWitt, Ph.D., Associate Professor, Department of Pharmacology & Toxicology, Brody School of Medicine, East Carolina University, Greenville, North Carolina

4. Edward Emmett, M.D., Professor, Center of Excellence in Environmental Toxicology, University of Pennsylvania, Philadelphia, Pennsylvania

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers’ comments and determine whether changes will be made to the profile based on comments. The peer reviewers’ comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

***DRAFT FOR PUBLIC COMMENT***
## CONTENTS

FOREWORD ........................................................................................................... ii
VERSION HISTORY .............................................................................................. iv
CONTRIBUTORS & REVIEWERS ........................................................................... v
CONTENTS ................................................................................................................. vi
LIST OF FIGURES ........................................................................................................ ix
LIST OF TABLES ......................................................................................................... xii

### CHAPTER 1. RELEVANCE TO PUBLIC HEALTH
1.1 OVERVIEW AND U.S. EXPOSURES ................................................................. 1
1.2 SUMMARY OF HEALTH EFFECTS ................................................................. 4
1.3 MINIMAL RISK LEVELS (MRLs) ................................................................. 15

### CHAPTER 2. HEALTH EFFECTS
2.1 INTRODUCTION ............................................................................................... 21
2.2 DEATH ............................................................................................................. 106
2.3 BODY WEIGHT ............................................................................................... 109
2.4 RESPIRATORY ............................................................................................... 121
2.5 CARDIOVASCULAR ....................................................................................... 123
2.6 GASTROINTESTINAL ..................................................................................... 135
2.7 HEMATOLOGICAL ......................................................................................... 137
2.8 MUSCULOSKELETAL ...................................................................................... 141
2.9 HEPATIC ........................................................................................................ 146
2.10 RENAL .......................................................................................................... 202
2.11 DERMAL ...................................................................................................... 219
2.12 OCULAR ....................................................................................................... 220
2.13 ENDOCRINE ............................................................................................... 221
2.14 IMMUNOLOGICAL ...................................................................................... 244
2.15 NEUROLOGICAL ......................................................................................... 293
2.16 REPRODUCTIVE .......................................................................................... 300
2.17 DEVELOPMENTAL ...................................................................................... 340
2.18 OTHER NONCANCER ................................................................................ 406
2.19 CANCER ...................................................................................................... 418
2.20 MECHANISM OF TOXICITY ......................................................................... 433
   2.20.1 Cellular Mechanisms of Toxicity ............................................................ 434
   2.20.2 Hepatic Toxicity Mechanisms ............................................................... 441
   2.20.3 Developmental Toxicity Mechanisms .................................................. 443
   2.20.4 Immunotoxicity Mechanisms ............................................................... 444
   2.20.5 Endocrine Mechanisms ...................................................................... 445
   2.20.6 Cancer Mechanisms ........................................................................... 446
2.21 GENOTOXICITY ............................................................................................ 447

### CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS
3.1 TOXICOKINETICS ......................................................................................... 450
   3.1.1 Absorption ............................................................................................ 450
   3.1.2 Distribution ........................................................................................... 451
   3.1.3 Metabolism ........................................................................................... 455
   3.1.4 Excretion ............................................................................................... 469

***DRAFT FOR PUBLIC COMMENT***
### CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION

#### 4.1 CHEMICAL IDENTITY

#### 4.2 PHYSICAL AND CHEMICAL PROPERTIES

### CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE

#### 5.1 OVERVIEW

#### 5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

- **5.2.1** Production
- **5.2.2** Import/Export
- **5.2.3** Use
- **5.2.4** Disposal

#### 5.3 RELEASES TO THE ENVIRONMENT

- **5.3.1** Air
- **5.3.2** Water
- **5.3.3** Soil

#### 5.4 ENVIRONMENTAL FATE

- **5.4.1** Transport and Partitioning
- **5.4.2** Transformation and Degradation

#### 5.5 LEVELS IN THE ENVIRONMENT

- **5.5.1** Air
- **5.5.2** Water
- **5.5.3** Sediment and Soil
- **5.5.4** Other Media

#### 5.6 GENERAL POPULATION EXPOSURE

#### 5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES

### CHAPTER 6. ADEQUACY OF THE DATABASE

#### 6.1 Existing Information on Health Effects

#### 6.2 Identification of Data Needs

#### 6.3 Ongoing Studies

### CHAPTER 7. REGULATIONS AND GUIDELINES

### CHAPTER 8. REFERENCES
LIST OF FIGURES

1-1. Health Effects Found in Animals Following Oral Exposure to PFOA ................................................. 7
1-2. Health Effects Found in Animals Following Oral Exposure to PFOS .................................................. 8
1-3. Health Effects Found in Animals Following Oral Exposure to Other Perfluoroalkyls ......................... 9
1-4. Summary of Sensitive Targets of PFOA – Oral ................................................................................. 17
1-5. Summary of Sensitive Targets of PFOS – Oral .................................................................................. 18
2-1. Overview of the Number of Studies Examining PFOA Health Effects .............................................. 27
2-2. Overview of the Number of Studies Examining PFOS Health Effects .............................................. 28
2-3. Overview of the Number of Studies Examining Other Perfluoroalkyls Health Effects ..................... 29
2-4. Levels of Significant Exposure to PFOA – Inhalation ....................................................................... 32
2-5. Levels of Significant Exposure to Other Perfluoroalkyls – Inhalation ................................................. 34
2-6. Levels of Significant Exposure to PFOA – Oral ................................................................................ 58
2-7. Levels of Significant Exposure to PFOS – Oral .................................................................................. 81
2-8. Levels of Significant Exposure to Other Perfluoroalkyls – Oral ........................................................ 99
2-9. Serum Total Cholesterol Levels Relative to Serum PFOA Levels ...................................................... 173
2-10. Risk of Abnormal Cholesterol Levels Relative to PFOA Levels (Presented as Adjusted Ratios) .............. 174
2-11. Serum LDL Cholesterol Levels Relative to Serum PFOA Levels ................................................... 175
2-12. Risk of Abnormal LDL Cholesterol Levels Relative to PFOA Levels (Presented as Adjusted Ratios) ...................................................................................................................... 176
2-13. Serum Total Cholesterol Levels Relative to Serum PFOS Levels .................................................. 189
2-14. Risk of Abnormal Cholesterol Levels Relative to PFOS Levels (Presented as Adjusted Ratios) .............. 190
2-15. Serum LDL Cholesterol Levels Relative to Serum PFOS Levels .................................................. 191
2-16. Risk of Abnormal LDL Cholesterol Levels Relative to PFOS Levels (Presented as Adjusted Ratios) ...................................................................................................................... 192
2-17. Risk of Hyperuricemia Relative to PFOA Levels (Presented as Adjusted Odds Ratios) .................... 213
2-18. Risk of Hyperuricemia Relative to PFOS Levels (Presented as Adjusted Odds Ratios) .................... 215

***DRAFT FOR PUBLIC COMMENT***
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-19</td>
<td>Antibody Responses Relative to Serum PFOA Levels in Epidemiology Studies</td>
<td>270</td>
</tr>
<tr>
<td>2-20</td>
<td>Risk of Asthma Diagnosis Relative to PFOA Levels (Presented as Adjusted Odds Ratios)</td>
<td>272</td>
</tr>
<tr>
<td>2-21</td>
<td>Antibody Responses Relative to Serum PFOS Levels in Epidemiology Studies</td>
<td>278</td>
</tr>
<tr>
<td>2-22</td>
<td>Risk of Asthma Diagnosis Relative to PFOS Levels (Presented as Adjusted Odds Ratios)</td>
<td>280</td>
</tr>
<tr>
<td>2-23</td>
<td>Antibody Responses Relative to Serum PFHxS Levels in Epidemiology Studies</td>
<td>283</td>
</tr>
<tr>
<td>2-24</td>
<td>Risk of Asthma Diagnosis Relative to PFHxS Levels (Presented as Adjusted Odds Ratios)</td>
<td>285</td>
</tr>
<tr>
<td>2-25</td>
<td>Antibody Responses Relative to Serum PFNA Levels in Epidemiology Studies</td>
<td>287</td>
</tr>
<tr>
<td>2-26</td>
<td>Risk of Asthma Diagnosis Relative to PFNA Levels (Presented as Adjusted Odds Ratios)</td>
<td>288</td>
</tr>
<tr>
<td>2-27</td>
<td>Antibody Responses Relative to Serum PFDeA Levels in Epidemiology Studies</td>
<td>290</td>
</tr>
<tr>
<td>2-28</td>
<td>Risk of Asthma Diagnosis Relative to PFDeA Levels (Presented as Adjusted Odds Ratios)</td>
<td>292</td>
</tr>
<tr>
<td>2-29</td>
<td>Fecundability Relative to PFOA Levels (Presented as Adjusted Fecundability Ratios)</td>
<td>326</td>
</tr>
<tr>
<td>2-30</td>
<td>Infertility Relative to PFOA Levels (Presented as Adjusted Odds Ratios)</td>
<td>327</td>
</tr>
<tr>
<td>2-31</td>
<td>Fecundability Relative to PFOS Levels (Presented as Adjusted Fecundability Ratios)</td>
<td>333</td>
</tr>
<tr>
<td>2-32</td>
<td>Infertility Relative to PFOS Levels (Presented as Adjusted Odds Ratios)</td>
<td>334</td>
</tr>
<tr>
<td>2-33</td>
<td>Risk of Low Birth Weight Infant Relative to PFOA Levels (Presented as Adjusted Odds Ratios)</td>
<td>379</td>
</tr>
<tr>
<td>2-34</td>
<td>Risk of Small For Gestational Age Infant Relative to PFOA Levels (Presented as Adjusted Odds Ratios)</td>
<td>380</td>
</tr>
<tr>
<td>2-35</td>
<td>Risk of Low Birth Weight Infant Relative to PFOS Levels (Presented as Adjusted Odds Ratios)</td>
<td>391</td>
</tr>
<tr>
<td>2-36</td>
<td>Risk of Small for Gestational Age Infant Relative to PFOS Levels (Presented as Adjusted Odds Ratios)</td>
<td>392</td>
</tr>
<tr>
<td>2-37</td>
<td>Diabetes Risk Relative to Serum PFOA Levels (Presented as Adjusted Ratios)</td>
<td>415</td>
</tr>
<tr>
<td>2-38</td>
<td>Diabetes Risk Relative to Serum PFOS Levels (Presented as Adjusted Odds Ratios)</td>
<td>417</td>
</tr>
<tr>
<td>3-1</td>
<td>Tissue Concentrations of $^{14}$C in Male and Female Rats Following a Single Gavage Dose of $[^{14}$C]PFOA at 1, 5, or 25 mg/kg</td>
<td>458</td>
</tr>
<tr>
<td>3-2</td>
<td>Tissue Concentrations of $^{14}$C in Male (Upper Panel) and Female (Lower Panel) Rats Following Oral Doses of PFOA for 28 Days at Doses of 3, 10, or 30 mg/kg/day</td>
<td>459</td>
</tr>
</tbody>
</table>
LIST OF TABLES

1-1. Summary of Estimated Elimination Half-lives for Select Perfluoroalkyls................................. 4
1-2. Overview of Provisional Minimal Risk Levels Derived for Perfluoroalkyl Compounds.......... 15
1-3. Provisional Minimal Risk Levels (MRLs) for PFOA................................................................. 19
1-4. Provisional Minimal Risk Levels (MRLs) for PFOS ............................................................... 19
1-5. Provisional Minimal Risk Levels (MRLs) for PFHxS............................................................... 20
1-6. Provisional Minimal Risk Levels (MRLs) for PFNA............................................................... 20
2-1. Levels of Significant Exposure to PFOA – Inhalation .............................................................. 30
2-2. Levels of Significant Exposure to Other Perfluoroalkyls – Inhalation..................................... 33
2-3. Levels of Significant Exposure to PFOA – Oral ................................................................... 35
2-4. Levels of Significant Exposure to PFOS – Oral .................................................................... 62
2-5. Levels of Significant Exposure to Other Perfluoroalkyls – Oral ............................................. 85
2-6. Levels of Significant Exposure to PFOA – Dermal ............................................................... 104
2-7. Summary of Childhood Growth in Humans....................................................................... 110
2-8. Summary of Cardiovascular Outcomes in Humans.............................................................. 125
2-9. Summary of Skeletal Outcomes in Humans ....................................................................... 142
2-10. Summary of Liver Disease in Humans.................................................................................. 148
2-11. Summary of Alterations in Serum Hepatic Enzymes and Bilirubin Levels in Humans ...... 150
2-12. Summary of Serum Lipid Outcomes in Humans................................................................. 156
2-13. Summary of Renal Outcomes in Humans.......................................................................... 203
2-14. Summary of Uric Acid Outcomes in Humans...................................................................... 206
2-15. Summary of Thyroid Outcomes in Humans....................................................................... 223
2-16. Summary of Immunological Outcomes in Humans............................................................ 245
2-17. Summary of Neurological Outcomes in Humans................................................................. 294
2-18. Summary of Alterations in Reproductive Hormone Levels in Humans............................... 301
2-19. Summary of Male Reproductive Outcomes in Humans...................................................... 308

***DRAFT FOR PUBLIC COMMENT***
2-20. Summary of Female Reproductive Outcomes in Humans .............................................................. 313
2-21. Summary of Fertility Outcomes in Humans ................................................................................... 318
2-22. Summary of Pregnancy Outcomes in Humans ............................................................................... 341
2-23. Summary of Birth Outcomes in Humans ........................................................................................ 344
2-24. Summary of Neurodevelopmental Outcomes in Humans  .............................................................. 360
2-26. Summary of Outcomes Related to Diabetes in Humans ..................................................................... 407
2-27. Summary of Cancer Outcomes in Humans ..................................................................................... 419
2-28. Transactivation of Human and Mouse PPARα in Transfected Cos-1 Cells Exposed to
        Perfluoroalkyl Compounds (In Order of Decreasing C20max in the Mouse) .................................... 436
2-29. Gene Expression Changes Induced by Perfluoroalkyl Compounds ............................................... 439
2-30. Hepatic Effects of Perfluoroalkyl Compounds in Wild-Type and PPARα-Null Mice
        Exposed Orally .................................................................................................................................... 442
3-1. Tissue Distribution and Excretion of 14C-Radioactivity from Both Sexes of Rats, Mice,
        Hamsters, and Rabbits Dosed with 14C-Labeled APFO .................................................................. 461
3-2. Serum (or Plasma) Concentrations in Matched Human Maternal-Infant Pairs .............................. 463
3-3. Matched Serum (or Plasma) and Breast Milk Concentrations in Humans ....................................... 467
3-4. Excretory Clearance of PFOA and PFOS in Humans ........................................................................... 471
3-5. Summary Elimination Half-Lives for Perfluoroalkyls Estimated in Humans and
        Experimental Animals ............................................................................................................................. 473
3-6. Summary Systemic Clearance for Perfluoroalkyls Estimated in Experimental Animals ................. 481
3-7. Estimated and Assumed Pharmacokinetic Parameters for the Modified Andersen et al.
        (2006) Model for PFOA and PFOS ...................................................................................................... 508
4-1. Chemical Identity of Perfluoroalkyls ................................................................................................ 522
4-2. Physical and Chemical Properties of Perfluoroalkyls ..................................................................... 527
5-1. Content (ppm) and Percent Reduction of PFOA, PFOA Homologues, or PFOA Precursors in
        Products from 2006 and 2013 U.S. Operations of Fluoropolymer/Fluorotelomer Companies ........ 541
        Inventory Update Rule .............................................................................................................................. 545

***DRAFT FOR PUBLIC COMMENT***
5-25. Percent Detection and Levels of Other Perfluoroalkyls in Children’s Serum, Umbilical Cord Blood, and Breast Milk


6-1. Ongoing Studies on Perfluoroalkyls

7-1. Regulations and Guidelines Applicable to Perfluoroalkyls

7-2. Select State Drinking Water and Daily Intake Levels for Perfluoroalkyls